Bold Therapeutics is a clinical-stage biopharma company based in Vancouver, British Columbia founded in 2018 to develop and commercialize BOLD-100, a first-in-class small molecule therapeutic with applications in both oncology (cancer) and infectious disease (COVID-19). Oncology.

Bold Therapeutics is developing BOLD-100 as a novel anti-cancer therapeutic. Bold Therapeutics is currently enrolling patients into a Phase 1/2 clinical study in advanced gastrointestinal cancers (2nd line gastric, pancreatic, colorectal and bile duct cancers) in combination with FOLFOX at six sites in Canada, with additional sites to be added in the United States and South Korea in late 2021 and early 2022. In established preclinical models, BOLD-100 significantly improved outcomes in a wide range of indications in combination with both traditional chemotherapies and targeted therapies. A previously completed Phase 1 monotherapy dose-escalation study showed that BOLD-100 was generally safe and well-tolerated with a safety profile suggesting that it could be combined with other anti-cancer therapies.

Infectious Disease (COVID-19). Bold Therapeutics has collaborated with infectious disease experts across Canada to develop BOLD-100 as a novel broad-spectrum antiviral. Initial results far exceeded expectations, with BOLD-100 demonstrating efficacy against not just SARS-CoV-2 (COVID-19), but a range of other viruses. In December 2020, Bold Therapeutics was one of only four therapeutics companies selected to receive COVID-19 funding and support from the Canadian government through NRC-IRAP. BOLD-100 is currently being tested in animal models of COVID-19 and expects to initiate clinical trials in COVID-19 later in 2021.